Skip to main content
Clinical Trials/NCT00564460
NCT00564460
Withdrawn
Phase 3

On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)

University of Alberta1 site in 1 countryFebruary 2008

Overview

Phase
Phase 3
Intervention
Finasteride
Conditions
Benign Prostatic Hyperplasia
Sponsor
University of Alberta
Locations
1
Primary Endpoint
To compare the incidence of red blood cell transfusion after TURP in BPH patients randomized to receive preoperative Finasteride with those randomized to receive placebo.
Status
Withdrawn
Last Updated
8 years ago

Overview

Brief Summary

Transurethral resection of the prostate (TURP) is a common treatment for benign prostatic hyperplasia (BPH). A common complication of TURP is blood loss. Preliminary data suggest that preoperative Finasteride, a 5 alpha-reductase inhibitor, may reduce blood loss during TURP. However, no study has examined the effect of preoperative Finasteride on clinical outcomes.

The study is a randomized, double-blind, placebo-controlled trial of preoperative Finasteride versus placebo in BPH patients undergoing TURP. Participants will be stratified by prostate volume (30 to 65 grams versus 66 to 100 grams) and randomly assigned to preoperative Finasteride or placebo. The primary end point is incidence of RBCT. Secondary end points are standard units of red blood cells transfused, variables related to perioperative bleeding (incidence of readmission, incidence of return to hospital, length of hospital stay), blood loss, change in serum hemoglobin, change in serum hematocrit, blood loss per gram of resected prostate tissue, operating time, change in AUA-SS, and change in HRQOL.

Detailed Description

The proposed trial is warranted for two main reasons. First, no study has examined the effect of preoperative Finasteride on important clinical outcomes such as the incidence of red blood cell transfusion, standard units of red blood cells transfused, readmission, return to hospital, and length of hospital stay. Second, a definitive randomized, double-blind, placebo-controlled trial documenting the efficacy of preoperative Finasteride on blood loss variables (e.g., intra-operative blood loss, change in serum hemoglobin) has yet to be conducted. Participants will be recruited from the practices of Credentialed Urologists at the Alberta Urology Institute (AUI) and UAH in Edmonton, Alberta, Canada. The eligibility criteria include medical, demographic, and logistic criterion, and focus on internal validity as well as external validity. Eligibility criteria for the study are: (1) TRUS-confirmed prostate gland \> 30 g, (2) 18 years of age or older, (3) fit and scheduled to receive TURP, (4) approval of the treating urologist, (5) able to understand and provide written informed consent in English, (6) no active psychiatric condition, (7) no previous Finasteride use, (8) normal DRE, (9) PSA greater than or equal to 4.0 ng/ml, (10) no current anticoagulation use (Heparin, Warfarin), (11) no ESRD, (12) no previous prostate or urethral surgery, and (13) not deemed to be a candidate for immediate surgery (within 1 week of initial evaluation).

Registry
clinicaltrials.gov
Start Date
February 2008
End Date
February 2011
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • TRUS-confirmed prostate gland \> 30 g,
  • 18 years of age or older,
  • fit and scheduled to receive TURP,
  • approval of the treating urologist,
  • able to understand and provide written informed consent in English

Exclusion Criteria

  • active psychiatric condition,
  • previous Finasteride use,
  • abnormal DRE,
  • PSA greater than 4.0 ng/ml,
  • current anticoagulation use (Heparin, Warfarin),
  • previous prostate or urethral surgery,
  • deemed to be a candidate for immediate surgery (within 1 week of initial evaluation).

Arms & Interventions

1

Finasteride 5 mg PO once daily for 8 weeks prior to TURP

Intervention: Finasteride

2

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

To compare the incidence of red blood cell transfusion after TURP in BPH patients randomized to receive preoperative Finasteride with those randomized to receive placebo.

Time Frame: During/post surgery

Secondary Outcomes

  • To compare standard units of red blood cells transfused, variables related to perioperative bleeding, blood loss, serum hemoglobin, serum hematocrit, blood loss per gram of resected prostate tissue, operating time, AUA-SS, HRQOL after TURP(during/post surgery)

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentAlcoholic hepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2020-004534-38-DEDURECT Corporation300
Active, not recruiting
Phase 1
OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)IgA nephropathy (IgAN)Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2018-000075-33-ESOmeros Corporation434
Active, not recruiting
Not Applicable
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney disease
EUCTR2012-002806-31-HUKAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)500
Active, not recruiting
Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
EUCTR2013-003713-18-ITMillennium Pharmaceuticals, Inc178
Active, not recruiting
Not Applicable
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Symptoms and general pathology [C23]
EUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500